Skip to main content
. 2022 Dec 8;9:1263–1278. doi: 10.2147/JHC.S347946

Figure 1.

Figure 1

Schematic picture of treatment efficacy of FASN inhibitor (TVB3664) alone or in combination with tyrosine kinase (sorafenib and cabozantinib) and immune checkpoint inhibitors (PD-L1 antibodies). The different genetic backgrounds of tumors were obtained by hydrodynamic tail vein injections in C57BL/6J mice.